|
1. BIOLOGIE
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Arguments on Drug Pricing [In The Pipeline]
|
|
|
|
|
|
I am not asking everyone to immediately agree with Booth’s points or Scannell’s: but I am asking anyone who wants to seriously talk about these issues to take those arguments seriously. There are (to put it mildly) a lot of people who speak very loudly and confidently about drug research and drug prices who have no idea what they are talking about.
|
|
|
|
|
|
|
|
Venturing A Perspective On The Drug Pricing Debate [Life Sci VC]
|
|
|
|
|
|
As a front-line practitioner in early stage biotech venture capital, I can assure you that radical across-the-board cuts in the future pricing of innovative therapies will certainly affect both the scale and pace of investments in new biomedical startups.
|
|
|
|
|
|
|
5.7.2 SABCS-DIVERS
|
|
|
|
5.7.4 SABCS-ESSAIS
|
|
|
|
|
|
5.7.4.1 SABCS-ESSAIS-TUCATINIB
|
|
|
|
|
|
5.7.4.2 SABCS-ESSAIS-TRASTUZUMAB DERUXTECAN
|
|
|
SABCS: AstraZeneca, Daiichi's ADC keeps breast cancer at bay for 16 months [Fierce Biotech]
|
|
|
|
|
|
But the data weren't all rosy. Nearly all of the patients (99%) experienced side effects, including nausea, vomiting and low white blood cell counts. Fifteen percent of patients decided to stop treatment due to side effects, according to the statement. Twenty-five patients developed interstitial lung disease (ILD), which is characterized by scarring in the lungs. Most of them had mild cases, but four people died from the disease.
|
|
|
|
|
|
|
|
|
|
|
|
|
5.7.4.3 SABCS-ESSAIS-PERTUZUMAB
|
|
|
|
|
|
|
5.7.4.4 SABCS-ESSAIS-MARGETUXIMAB
|
|
|
|
|
5.8.3 ASH - DIVERS
|
|
|
|
5.8.6 ASH - LEUCÉMIES
|
|
|
|
6.6 PUBLICATIONS
|
|
|